S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

$52.86
+1.31 (+2.54 %)
(As of 01/20/2020 10:38 AM ET)
Today's Range
$51.71
Now: $52.86
$53.27
50-Day Range
$38.71
MA: $46.34
$52.86
52-Week Range
$28.36
Now: $52.86
$68.94
Volume1.60 million shs
Average Volume674,075 shs
Market Capitalization$3.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$94.39 million
Book Value$11.82 per share

Profitability

Net Income$-346,020,000.00
Net Margins-356.42%

Miscellaneous

Employees482
Market Cap$3.11 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.


Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, beating the consensus estimate of ($1.85) by $0.04. The biopharmaceutical company had revenue of $26.02 million for the quarter, compared to the consensus estimate of $33.13 million. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. The company's revenue for the quarter was up 71.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.63) earnings per share. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

13 equities research analysts have issued 12-month price objectives for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $80.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $65.50 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

Media stories about AGIO stock have been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Agios Pharmaceuticals.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), Micron Technology (MU), NVIDIA (NVDA) and Allergan (AGN).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.27%) and Steward Partners Investment Advisory LLC (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Steward Partners Investment Advisory LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $52.86.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.11 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com/.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  767
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel